Skip to content

A single center, open label study to evaluate the antimicrobial efficacy of Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel as per CEN 1499 Standard on healthy volunteers

A single center, open label study to evaluate the antimicrobial efficacy of Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel as per CEN 1499 Standard on healthy volunteers

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/05/005816
Enrollment
14
Registered
2015-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel: Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel for external use. Dosages of drug: 2 X 3ml over 60 seconds. Control Interventi

Sponsors

Dishman Pharmaceuticals Chemicals Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I. Healthy male & female volunteers between 18 to 65 years of age. II. Volunteers must possess both hands. III. Volunteers must be free of dermatoses, cuts, lesions, hangnails, or other skin disorders on hands and forearms. IV. Volunteers must not have used topical or systemic antimicrobials, antibiotics, or steroids for the one week pre-test and must agree to abstain from these materials until the completion of the study. V. Volunteers must be in good health. VI. Volunteers must have read and signed the Informed Consent Form. VII. Volunteers should not have any past medical history of sensitivity to the use of such products. VIII. Should not have known sensitivity to the treatment constituents. IX. Volunteers should be able to read, write and understand English language.

Exclusion criteria

Exclusion criteria: I. A current skin disease of any type (e.g. eczema, psoriasis). II. Cuts, abrasions or open wounds on the hands. III. Known sensitivity to the treatment constituents. IV. Exposure of ungloved hands and forearms to antimicrobial agents, medicated soaps, medicated shampoos, medicated lotions or use of biocide-treated pools or hot tubs during the seven days pre-test or on the single test day. V. Exposure or ungloved hands or forearms to strong detergents, solvents or other irritants during the seven days pre-test or on the single test day. VI. Use of systemic or topical antibiotic medications during the seven days pre- test period or on the single test day. VII. Known allergies to Octenidine Dihydrochloride Compounds or any of the ingredients of test and reference formulations. VIII. Pregnancy plans to become pregnant within the seven days pre-test and test periods of the study or nursing a child. IX. Any active skin rashes or breaks in the skin of hands or forearms. X. A currently active skin disease or inflammatory skin condition, including contact dermatitis. XI. Pregnant or lactating female volunteer. XII. Participation in a clinical study in the past thirty days or current participation in another clinical trial. XIII. Unwillingness to fulfill the performance requirements of the study.

Design outcomes

Primary

MeasureTime frame
â?¢ To evaluate and compare the antimicrobial effectiveness of a Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel Vs. propanol-2-ol (60%) disinfectant solution when used for hygienic handwash purpose.Timepoint: â?¢ To evaluate and compare the antimicrobial effectiveness of a Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel Vs. propanol-2-ol (60%) disinfectant solution when used for hygienic handwash purpose.

Secondary

MeasureTime frame
â?¢ To determine the tolerability of Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel.Timepoint: All SAEâ??s occurring during the study must be reported to the sponsor by telephone or fax within 24 hours of the investigator becoming aware of the SAE.

Countries

India

Contacts

Public ContactDr Bula Aruna MD Microbiology

Rajiv Gandhi Institute of Medical Sciences & RIMS Govt. General Hospital

rimsresearch@gmail.com08942-279033

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026